These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12503842)

  • 1. Maintained improvement with minocycline of a patient with advanced Huntington's disease.
    Denovan-Wright EM; Devarajan S; Dursun SM; Robertson HA
    J Psychopharmacol; 2002 Dec; 16(4):393-4. PubMed ID: 12503842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why minocycline is helpful in Huntington's disease.
    Bonelli RM; Kapfhammer HP
    J Psychopharmacol; 2003 Dec; 17(4):461. PubMed ID: 14870963
    [No Abstract]   [Full Text] [Related]  

  • 3. Revisiting safety of minocycline as neuroprotection in Huntington's disease.
    Reynolds N
    Mov Disord; 2007 Jan; 22(2):292. PubMed ID: 17083098
    [No Abstract]   [Full Text] [Related]  

  • 4. Huntington's disease and minocycline.
    Hödl AK; Bonelli RM
    Mov Disord; 2005 Apr; 20(4):510-511. PubMed ID: 15806589
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minocycline in Huntington's disease: a pilot study.
    Thomas M; Ashizawa T; Jankovic J
    Mov Disord; 2004 Jun; 19(6):692-5. PubMed ID: 15197710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minocycline and doxycycline are not beneficial in a model of Huntington's disease.
    Smith DL; Woodman B; Mahal A; Sathasivam K; Ghazi-Noori S; Lowden PA; Bates GP; Hockly E
    Ann Neurol; 2003 Aug; 54(2):186-96. PubMed ID: 12891671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minocycline is protective in a mouse model of Huntington's disease.
    Hersch S; Fink K; Vonsattel JP; Friedlander RM
    Ann Neurol; 2003 Dec; 54(6):841; author reply 842-3. PubMed ID: 14681897
    [No Abstract]   [Full Text] [Related]  

  • 9. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease.
    Diguet E; Rouland R; Tison F
    Ann Neurol; 2003 Dec; 54(6):841-2. PubMed ID: 14681898
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical potential of minocycline for schizophrenia.
    Miyaoka T
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):376-81. PubMed ID: 18991666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A futility study of minocycline in Huntington's disease.
    Huntington Study Group DOMINO Investigators
    Mov Disord; 2010 Oct; 25(13):2219-24. PubMed ID: 20721920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease.
    Thomas M; Le WD; Jankovic J
    Clin Neuropharmacol; 2003; 26(1):18-23. PubMed ID: 12567160
    [No Abstract]   [Full Text] [Related]  

  • 14. Minocycline for Huntington's disease: an open label study.
    Bonelli RM; Heuberger C; Reisecker F
    Neurology; 2003 Mar; 60(5):883-4. PubMed ID: 12629257
    [No Abstract]   [Full Text] [Related]  

  • 15. Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.
    Pattison LR; Kotter MR; Fraga D; Bonelli RM
    J Neurol; 2006 Sep; 253(9):1137-42. PubMed ID: 16998646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.
    Chen M; Ona VO; Li M; Ferrante RJ; Fink KB; Zhu S; Bian J; Guo L; Farrell LA; Hersch SM; Hobbs W; Vonsattel JP; Cha JH; Friedlander RM
    Nat Med; 2000 Jul; 6(7):797-801. PubMed ID: 10888929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible antipsychotic effects of minocycline in patients with schizophrenia.
    Miyaoka T; Yasukawa R; Yasuda H; Hayashida M; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):304-7. PubMed ID: 17030375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection in Huntington's disease: a 2-year study on minocycline.
    Bonelli RM; Hödl AK; Hofmann P; Kapfhammer HP
    Int Clin Psychopharmacol; 2004 Nov; 19(6):337-42. PubMed ID: 15486519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
    Ryu JK; Choi HB; McLarnon JG
    Neuroscience; 2006 Sep; 141(4):1835-48. PubMed ID: 16809003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
    Diguet E; Fernagut PO; Wei X; Du Y; Rouland R; Gross C; Bezard E; Tison F
    Eur J Neurosci; 2004 Jun; 19(12):3266-76. PubMed ID: 15217383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.